Summary Patients hospitalised for exacerbations contribute significantly to the total chronic obstructive pulmonary disease (COPD)-related healthcare costs. This study aimed to determine the resource use and costs of exacerbations by exacerbation-severity and to identify risk factors for hospitalisation.
Introduction
Chronic obstructive pulmonary disease (COPD) is a highly prevalent, progressive degenerative respiratory disorder and a major cause of disability and premature death. COPD morbidity and mortality are increasing worldwide, due to increasing numbers of smokers, especially among women, and the ageing of the population. 1 Consequently, an alarming worldwide increase in the burden and costs of COPD is projected for the foreseeable future. [2] [3] [4] Many patients with COPD experience recurrent exacerbations defined as episodes of worsening breathlessness and/or wheeze, often accompanied by greater volume or purulence of sputum and increased cough. 5, 6 Exacerbations contribute to a more rapid decline in lung function, 7 morbidity and poorer quality of life 8 as well as to increased healthcare costs. They are the main reason for COPD-related hospital admission, often after failed initial exacerbation-therapy in the community. 9 Estimates of the costs of exacerbations vary from DM 297 (1998, Euros: 152) per exacerbation in a German study, 10 SEK 3136 (1999, Euros 344) in a Swedish study 11 to FF 3,289 (1994, Euros 501) in a French study. 12 The Swedish and German studies show the costs to rise considerably with the severity of the exacerbation. All of these studies report that inpatient hospital care is the major cost driver, responsible for 67%, 60% and 44% of the exacerbation-related costs in the Swedish, French and German study, respectively. The difference in cost estimates between these studies is remarkable and probably due to a variety of factors including differences in definitions, patient populations, treatment patterns and methods of data collection. Moreover, the classification of exacerbation-severity is based on the resource use associated with exacerbations, which of course reinforces the association between severity and costs.
To reduce the costs of exacerbations, we need to know more about risk factors for hospital admission, as this is the major cost driver. Such knowledge would enable us to better target new treatments and to minimise healthcare costs in patients with COPD. The goal of the present study was to determine the costs of exacerbations by exacerbation-severity and identify risk factors associated with high-cost exacerbations in patients whose COPD was considered stable at entry into the study. The classification of the severity of exacerbations was based on physicians' assessments and a very detailed record was kept of all relevant types of healthcare utilisation associated with exacerbations.
Methods

Design trials
This analysis was based on data from a prospective cost-effectiveness analysis linked to two randomised controlled double-blind trials comparing 18 mg tiotropium (Spiriva s ) inhalation capsules administered once daily via the HandiHaler s device with ipratropium (Atrovent s ) 2 puffs of 20 mg administered four times daily via the metered dose inhaler (MDI). The design and results of the trials and the economic evaluation have been published elsewhere. 13, 14 In brief, patients with a diagnosis of COPD and a relatively stable airway obstruction defined as an FEV 1 p65% of predicted normal and FEV 1 p70% of FVC were randomised to either tiotropium (n ¼ 344) or ipratropium (n ¼ 175) in a ratio of 2:1. Patients were aged over 40 and had a smoking history of at least 10 packyears. Patients with a diagnosis of asthma were excluded. One trial was performed in the Netherlands and the other in the Netherlands and Belgium. Because the design of these trials was identical the data were combined. After a 2-week run-in period, patients were seen at regularly scheduled follow-up visits 1, 4, 7, 10, 13, 19, 26, 32, 29, 45 and 52 weeks after randomisation, during which healthcare resource use, health outcomes and adverse events, including COPD exacerbations were recorded. The trials were approved by the medical ethics committees of the participating hospitals, and all patients gave written informed consent.
Exacerbations
All COPD exacerbations were recorded as adverse events in the case report forms (CRF). A COPD exacerbation was defined as a complex of respiratory symptoms (i.e. new onset or worsening of more than one symptom such as cough, sputum, dyspnea or wheeze) lasting for at least 3 days. Exacerbations were classified in the CRF as either mild, moderate or severe based on ratings by the physician-investigator. A mild exacerbation was defined as 'awareness of a sign or symptom which is easily tolerated', a moderate exacerbation as 'an exacerbation causing discomfort enough to cause interference with usual activity' and a severe exacerbation was defined as 'an exacerbation that was incapacitating or causing inability to do work or usual activity'.
Resource use and costs
A very detailed record was kept of all relevant types of healthcare utilisation associated with exacerbations, including: hospital admissions and length of stay (ICU and non-ICU days), emergency room visits, visits to respiratory physicians, GPs and other healthcare providers that were not scheduled in the clinical trial protocol, ambulance transportations, tests, rescue medication (salbutamol MDI, 1 puff ¼ 100 mcg) and other respiratory medications including antibiotics. When a COPD exacerbation was associated with a hospital admission this was recorded by the physician-investigator in the CRF. At the end of the trial, all hospital admissions were verified using hospital chart audit. When hospitalised patients withdrew from the study before they were discharged, the total length of hospital stay was taken into account, including the days after withdrawal. To calculate the medication costs during exacerbations, we only included those new respiratory medications that patients started to take during the exacerbation and the dose increases of respiratory medication that patients were already taking before the onset date of the exacerbation. Costs of new medications and dose increases were calculated until the end date of the prescription, with a maximum duration of 3 weeks after the end date of the exacerbation in case the new medication or new dose was continued. All changes in dose during the exacerbation and the 3 weeks thereafter were taken into account.
Costs were calculated by multiplying the resource use related to exacerbations with unit costs for the Netherlands (year 2001 prices).
14 All healthcare costs were included in the analysis and calculated from the societal perspective. This implies that all healthcare costs were taken into account, regardless of whether they were borne by government, private or public insurers, or the patients and their families. In addition, unit costs of the major cost drivers were based on estimates of real resource use and not reimbursements. Caregiver and productivity costs were not included.
Statistical analyses
Differences in baseline characteristics between patients with and without exacerbations were tested using t-tests for continuous variables and chi-square tests for categorical variables. Bootstrapping was used to determine 95% confidence intervals around estimates of the duration, resource use and costs of exacerbations by severity. The univariate association between baseline-variables and time to hospital admission were investigated using log-rank tests. In case of continuous variables, the median was used to create two groups. Except for the BMI which was dichotomised using the underweight criterion of 18.5. 15 The independent contribution of each potential risk factor for hospitalisation was investigated using a Cox proportional hazards analysis. Covariates selected for the Cox analysis included: BMI (0 : X18:5; 1 : o18:5), smoking status (0: ex-smoker, 1: current smoker) and smoking pack-years, number of concomitant diagnoses, number of unscheduled physician visits prior to trial, use of inhaled corticosteroids (0: no steroid use, 1: steroid use) and number of concomitant medications, baseline dyspnea index (BDI), FEV 1 % predicted normal and the total score of the St. George's Respiratory Questionnaire (SGRQ). To verify whether the associations between FEV 1 % predicted and hospitalisation and the SGRQ total score and hospitalisation became stronger when not only the baseline values of these parameters were considered, we also performed an analysis in which FEV 1 % predicted and the SGRQ total score were entered as time dependent variables (i.e. an analysis based on four strata of 3 months in which the FEV 1 and SGRQ measurements of the beginning of each stratum were used). The Cox regressions were performed with SPSS 11.0.1, using a backward stepwise elimination procedure, selecting covariates with a P-value ( 0:1: Variable independency was checked by inspection of the correlation matrix. The assumption of proportional hazards was checked using a log-minus-log survival plot.
Results
Patients
Five hundred and thirty-five patients were randomised of whom 519 had completed at least one visit after randomisation. The baseline characteristics of these 519 patients are shown in Table 1 , comparing patients with and without exacerbations. The mean age of patients was 64 (SD 8) years and 440 (85%) were male. Compared to patients who had no exacerbations during the observation period, patients who experienced at least one exacerbation had significantly more concomitant diagnoses (2.6 versus 2.2, P ¼ 0:007), higher use of concomitant medications (2.9 versus 2.4, P ¼ 0:007), lower FEV 1 % predicted (37.5 versus 41.2, P ¼ 0:001), worse health status (SGRQ total score 48.7 versus 42.3, Po0:001) and more dyspnea at baseline (BDI 6.7 versus 7.5, P ¼ 0:001).
Exacerbations
The 519 patients included in the current analysis experienced 364 exacerbations. The mean number of exacerbations was 0.70 (95% CI:0.60-0.81) per patient and the mean number of exacerbation-days was 11.32 (95% CI:9.34-13.30) per patient. After correcting for differences in the duration that patients remained in the study, the mean number of exacerbations and exacerbation-days per patient-year were 0.80 and 12.97, respectively. About 40% (n ¼ 207) of the 519 patients experienced at least one exacerbation. The maximum number of exacerbations in one patient was nine. The mean duration of an exacerbation was 16.1 (95% CI:14.8-17.6) days and the median duration was 12 days. About 10% (n ¼ 36) of the exacerbations was severe, 47% (n ¼ 173) moderate and 43% (n ¼ 155) mild. The mean (median) duration of a severe exacerbation was 25.3 (20) days (95% CI:19.8-31.3), which was significantly longer than the mean (median) duration of moderate and mild exacerbations which were 16.6 (13) days (95% CI:14.7-18.9) and 13.5 (11) days (95% CI:12.1-15.1), respectively.
Resource use during exacerbations
Healthcare resource use data were complete for 350 of the 364 exacerbations (Table 2) . Of the severe exacerbations, 78% (n ¼ 28) was associated with at least one hospital admission and 25% (n ¼ 9) with at least one ER-visit. Of the moderate exacerbations, 16% (n ¼ 26) was associated with a hospital admission and 5% (n ¼ 8) with a visit to the ER. Only in 1 case, a patient was hospitalised when experiencing an exacerbation rated as mild by the clinician. In case of a hospitalisation, the mean (median) length of stay was 15.4 (14) (95% CI: 12.5-19.2) days for a severe exacerbation and 11.8 (10) Table 3 presents the unit costs of the major resource use items and the mean costs per exacerbation by severity. The mean cost of an exacerbation was Euro 720 (95% CI:515-1003). The mean costs of severe exacerbations were Euro 4007 (95% CI:2551-6366), which was approximately 7 times higher than the mean costs of moderate exacerbations (Euro 579, 95% CI:407-769) and 47 times as high as the costs of mild exacerbations (Euro 86, 95% CI:60-130). The median costs of mild, moderate and severe exacerbations were Euro 49, 86 and 2824, respectively. About 86% of the costs of severe exacerbations resulted from inpatient hospital days and 6% from diagnostic tests. Despite the relatively low percentage of hospitalisations in moderate exacerbations (16%), hospitalisation costs accounted for 71% of the costs of moderate exacerbations. In mild exacerbations, concomitant medications were the main cost driver and accounted for 37% of the total costs whereas unscheduled visits accounted for 33% of the total costs. Costs of concomitant medications varied considerably with exacerbation severity and ranged from Euro 158 (95% CI :90-249) for a severe exacerbation to Euro 32 (95% CI:27-37) for a mild exacerbation. Fig. 1 shows the costs of medications during exacerbations. About 58% of these costs were due to antibiotics and about 22% due to systemic corticosteroids. Fig. 2 shows the relationship between the proportion of exacerbations and the proportion of total costs of exacerbations. The curve has a steep slope at the beginning, indicating that a small number of exacerbations accounted for a large part of the total costs. The 16% of exacerbations that were associated with a hospitalisation accounted for approximately 90% of the total costs of exacerbations. About half of these exacerbations were rated severe and the other half was rated moderate. The total costs of all exacerbations accounted for approximately 34% of the total respiratory-related healthcare costs that were calculated in the original economic evaluation. 14 Table 4 shows the univariate association between patient characteristics and the Kaplan-Meier estimate of the cumulative proportion of patients with hospitalisation. A low BMI, a high number of concomitant diagnoses, a high number of respiratory medications, a low BDI score and assignment to the ipratropium treatment arm were significantly associated with an increased risk of hospitalisation. The largest differences in the proportions of patients with hospitalisation were found between In case of continuous variables the median was used to create two groups. BMI was split into two groups using the underweight criterion of 18.5 (15) . w Cumulative proportions based on Kaplan-Meier curves.
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patients with a history of more or less than two concomitant diagnoses (0.19 versus 0.06) and between patients with a BMI below or above 18.5 (0.37 versus 0.10).
In the Cox proportional hazards analysis BMI, treatment group, the number of concomitant diagnoses at baseline and BDI were independent risk factors of hospital admission ( Table 5 ). The risk of hospitalisation for patients with a BMI below 18.5 was 3.6 times higher than for patients without underweight. A 1-unit decrease ( ¼ increased dyspnea) in the BDI increased the risk of hospitalisation by 18.2% and each additional diagnosis increased the hazard rate by 40.4%. Patients treated with tiotropium experienced less than half the hospitalisation risk of patients treated with ipratropium. The correlation matrix showed that the Pearson correlation coefficients between the 11 variables that entered the model at the start were always less than 0.37, except for the BDI and the SGRQ. These two variables were highly correlated (Pearson R: 0.651; Po0:001). When the baseline values of both were entered, the BDI proved to be a more powerful predictor. When the BDI was left out, the SGRQ demonstrated an increased risk of hospitalisation of 8% for each 4 units increase ( ¼ worsening) in the SGRQ total score. Entering FEV 1 % predicted and the SGRQ as timedependent variables did not improve the model, nor did adding the SGRQ domains instead of the SGRQ total score. Excluding treatment arm as a covariate did not lead to a statistical significant contribution of other risk factors, while the other significant covariates in the model were hardly affected.
Discussion
About 40% of the patients whose COPD was judged to be stable at entry into the current study experienced at least 1 exacerbation and the mean number of exacerbations per patient-year was 0.80. The mean duration of an exacerbation was 16 days. There was a wide variation in the costs of exacerbations, ranging from Euro 4007 for a severe exacerbation to Euro 579 and Euro 86 for moderate and mild exacerbations. About 16% of the exacerbations was associated with a hospital admission and these exacerbations were responsible for about 90% of the total costs of exacerbations. A BMI below 18.5, a higher number of concomitant diagnoses and increased dyspnea (a low BDI score) at baseline were significantly associated with an increased risk of hospitalisation. In addition, treatment with tiotropium reduced the risk of hospitalisation by 57% compared to ipratropium.
The definition of exacerbation severity was based on physicians' assessments of the extent to which an exacerbation interfered with the ability to perform usual activities. Previous studies have used health care resource use to define severity. In such a classification, severe exacerbations are often defined as those associated with a hospital admission, moderate exacerbations as those associated with an outpatient visit with or without the prescription of an oral steroid or an antibiotic, and mild exacerbations as those that are primarily self-managed. We did not adopt this definition because treatment patterns are likely to vary across settings. An exacerbation that is severe in one country might not be rated as severe in another country because the countries may use different criteria to hospitalise a COPD patient. However, when we applied this definition to our study, we observed a further increase of the difference in costs between severe exacerbations (Euro 4117) on the one hand and moderate (Euro 123) and mild exacerbations (Euro 29) on the other hand, signify- ing the large impact of hospitalisations on the cost per exacerbation.
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The Cox proportional hazard analysis showed that, apart from treatment group, a low BMI, a higher number of concomitant diagnoses and dyspnea measured with the BDI were significantly associated with hospitalisation. The BDI was a better predictor than FEV 1 , which is generally considered to be the most important marker of COPD severity. Even when BDI was removed from the model, FEV 1 was not identified as an independent risk factor for hospital admission. This finding is in line with other studies, which reported that dyspnea was predictive of (severe) re-exacerbations 8 and mortality. 16 Dyspnea might ''reflect more comprehensive information than airway obstruction'' 17 and might be a marker of COPD severity that is at least as important as FEV 1 . Especially when dyspnea is measured with an instrument like the BDI, which also covers the functional aspects of breathlessness as assessed by the patient. This probably explains part of the interchangeability between the BDI and the SGRQ. The SGRQ has been shown to predict hospital admission before. 18 When BDI was removed from the model, the SGRQ became a significant risk factor of hospitalisation, whereas the coefficients of the other significant covariates were hardly affected. When both were entered, the BDI appeared to be more powerful. Even when the SGRQ was entered as a timedependent variableFto study whether quality of life in the period before the hospitalisation is a better predictor than quality of life at baselineFthe BDI continued to show a stronger association with hospital admission than the SGRQ.
Strengths of the current study were the prospective and detailed collection of data about exacerbations and resource use. It should be noticed, however, that these data were collected in a clinical trial setting. As in most clinical trials, patients were monitored closer than in daily practice. There is always a risk that the regularly scheduled trial visits substitute visits that would have occurred if the trial had not taken place. On the other hand, patients in a trial are often more strongly encouraged to contact the physician when their condition deteriorates. The trial was performed in a population of stable COPD patients with less comorbidity than in the average COPD population. Even in this population, we found that exacerbations accounted for approximately 34% of the total respiratory-related healthcare costs. 14 This 34% compares well to a Swedish observational study that applied very few selection criteria. In that study it was found that approximately 35-45% of the costs of COPD treatment were due to exacerbations. 11 These percentages are very different from a number of database-studies reporting costs in the US. 19, 20 Although these studies did not explicitly relate costs to exacerbations, it was estimated that approximately 70% of the costs of treating patients with COPD were due to hospitalisations. This higher percentage is probably related to the higher unit costs of an inpatient hospital day in the US, but may also be due to differences in treatment patterns and study design. The data at least suggest that there are large differences in the costs of treating COPD across countries, which may have large impacts on the cost-effectiveness of (new) treatments in COPD. Any treatment that successfully prevents severe exacerbations and costly hospitalisations is likely to be most cost-effective in countries with high costs of hospitalisation.
In conclusion, many patients whose COPD is judged to be stable experience exacerbations. According to our definition of severity, roughly 40% of the exacerbations was mild, 50% was moderate and 10% was severe. Costs of severe exacerbations were approximately 7 and 47 times as high as the costs of moderate and mild exacerbations, respectively. Exacerbations that were associated with a hospitalisation accounted for 90% of the total costs of exacerbations. A low BMI, a history of concomitant diseases and increased dyspnea are factors that are likely to identify patients who are at increased risk of generating high costs as a result of hospitalisation.
